Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T21:41:18.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study record content with an access-denied screen. As a result, the core trial details and navigation are no longer visible, hindering user access to sponsor information, locations, eligibility criteria, and interventions.
    Difference
    19%
    Check dated 2026-09-22T22:39:05.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The revision label on the page was updated from v3.6.6 to v3.7.0. This indicates an updated edition of the study documents.
    Difference
    0.0%
    Check dated 2026-09-15T20:47:08.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, signaling a new build of the page. It likely reflects minor fixes or updates to the page rather than changes to the study data.
    Difference
    0.0%
    Check dated 2026-09-01T18:20:04.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    A new line '2018 ( U.S. NIH Grant/Contract )' was added to the study's identifiers section. This records NIH funding information associated with the trial.
    Difference
    0.0%
    Check dated 2026-08-25T19:49:22.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    The page now shows an updated revision label Revision: v3.6.5, and the Plain Language Summary section has been removed along with the older Revision: v3.6.4.
    Difference
    0.0%
    Check dated 2026-08-11T18:55:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.